about
Guideline for collection, analysis and presentation of safety data in clinical trials of vaccines in pregnant womenIncreased Risk of Group B Streptococcus Invasive Infection in HIV-Exposed but Uninfected Infants: A Review of the Evidence and Possible MechanismsEvaluation of the Immunomodulatory Properties of Streptococcus suis and Group B Streptococcus Capsular Polysaccharides on the Humoral Response.Prevention of group B streptococcal neonatal disease revisited. The DEVANI European project.Serotypes, antibiotic susceptibilities, and multi-locus sequence type profiles of Streptococcus agalactiae isolates circulating in Beijing, China.Capsular gene typing of Streptococcus agalactiae compared to serotyping by latex agglutinationRisk factors for Group B Streptococcus colonisation and disease in Gambian women and their infants.Group B Streptococcus induces a caspase-dependent apoptosis in fetal rat lung interstitium.Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine.Group B Streptococcus and Streptococcus suis capsular polysaccharides induce chemokine production by dendritic cells via Toll-like receptor 2- and MyD88-dependent and -independent pathwaysGuidance for the collection of case report form variables to assess safety in clinical trials of vaccines in pregnancy.Group B streptococcal disease and genotypes in Australian infants.Group B streptococcal immunisation of pregnant women for the prevention of early and late onset Group B streptococcal infection of the neonate as well as adult disease.Capsular switching in group B Streptococcus CC17 hypervirulent clone: a future challenge for polysaccharide vaccine development.Preventing newborn infection with maternal immunization.Epidemiology of invasive group B streptococcal disease in infants from urban area of South China, 2011-2014.Vaccines in clinical trials: infectious disease.Development of a multiplexed opsonophagocytic killing assay (MOPA) for group B Streptococcus.Novel, Broadly Reactive Anticapsular Antibodies against Carbapenem-Resistant Klebsiella pneumoniae Protect from Infection.
P2860
Q26250281-3153D6D9-C5BE-431B-8A4C-2B9488801BCFQ28067423-DB4FCF5E-FBB1-4A83-892A-4FB4C5EC68F1Q33847250-2491C450-F671-43AB-9F4E-1EA2DEEDC907Q34252808-1D266052-73E7-47C5-A4C1-F0C045BFAFE9Q35188390-D679C270-C0A4-4F71-9A81-55EF74607D64Q36559104-4746835B-4BA2-4B90-8EBF-A7D76C2B5367Q36624991-DA0BCF48-637D-4294-9F13-FA11C0C0A1C1Q36997087-E81DDEB0-DDBD-444A-A4DD-A68064A2E14AQ37074015-96AA6F04-0879-4CA1-ADB9-D6FC756BC4B8Q37123791-03705C51-BCFF-4293-A58B-1AD3E0CD523CQ37477687-287118FA-4138-4E05-98F6-FF9D350272A2Q38345971-3E891D47-888F-4BA0-B892-8D87296E01F6Q38844623-A9B742AF-BBC7-4B45-A836-A5BD5A9FF12EQ39548543-6F601851-4FE0-4A5E-BE9D-D9EDA98E45F0Q42253830-AA7DEE02-CE67-4601-B8D6-F364C2D56117Q47196377-66172917-EB85-4FA7-A391-E8AF6D487885Q47980661-0F797937-0234-4EA2-90A9-911DDEA0B727Q48053443-EC19C4FD-0FE7-4207-AD0F-8EC13C2D1306Q52609091-9D709C3D-D446-499F-8B3F-A4E9F3782B93
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
An update on vaccination against group B streptococcus.
@en
An update on vaccination against group B streptococcus.
@nl
type
label
An update on vaccination against group B streptococcus.
@en
An update on vaccination against group B streptococcus.
@nl
prefLabel
An update on vaccination against group B streptococcus.
@en
An update on vaccination against group B streptococcus.
@nl
P2860
P356
P1476
An update on vaccination against group B streptococcus.
@en
P2860
P304
P356
10.1586/ERV.11.61
P50
P577
2011-05-01T00:00:00Z